News brief: Estrogen receptor-alpha, breast cancer patients and tamoxifen response

(Journal of the National Cancer Institute) Researchers have found evidence of a statistically significant survival benefit from adjuvant tamoxifen among patients whose estrogen-receptor-positive tumors had high levels of phosphorylation of ER-alpha; at serine-118, according to a brief communication published online Nov. 25 in the Journal of the National Cancer Institute.

source : www.eurekalert.org

Related News:

• Kidney Cancer Drug Shows Promising Results
• Launch Of Ipsen’s Decapeptyl(R) 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Prostate Cancer
• Barker Hypothesis Strengthened By Ancient Tooth Remains
• Scientists At Rice University Discover That ‘Nanobubbles’ Kill Cancer
• AM: Opioid Gains Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Launch Of Ipsen’s Decapeptyl 6-Month Formulation (LP 22.5 Mg) In France For The Treatment Of Advanced Or Metastatic Hormone-Dependent Prostate Cancer
• Green Tea Extracts Halt Growth of Prostate Cancer Tumors
• AM: Opioid Shows Long-Term Control of Neuropathic Cancer Pain (CME/CE)
• Recordati : Silodosin Approved By The European Commission For The Treatment Of The Signs And Symptoms Of Benign Prostatic Hyperplasia
• EMEA Gives Official Scientific Advice On Clinical Phase IIb Efficacy Study Of Inecalcitol In Hormone-refractory Prostate Cancer

Details :
Submited at Wednesday, November 25th, 2009 at 7:00 pm on Cancer and Oncology by madison
Comment RSS 2.0 - leave a comment - trackback